ASH 2018 | CAR T-cell updates in CLL
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
In this interview, William Wierda, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, reveals the lower response rates seen with CAR T-cell therapy in patients with chronic lymphocytic leukemia (CLL) when compared to other diseases, such as acute lymphoblastic leukemia (ALL). Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. Wierda discusses the improvements being made to enhance these response rates, before introducing the latest data on CLL treatments, with particular reference to novel small molecule inhibitors.
Get great new content delivered to your inboxSign up